AIM ImmunoTech Inc. fell 12.5% on Tuesday, November 10, 2026, on 1,849,400 shares. The headline around the move:
AIM ImmunoTech Inc. (AIM:NYSEMKT) closed at $0.144 on November 13, 2026, down 3.36% on the day. The stock trades 92.1% below its 52-week high of $1.82 and 19.7% above its 52-week low of $0.120. Over the past year, it lost 89.5%. AIM ImmunoTech Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since November 13, 2025, AIM closed higher on 76 days (30%). Its best day was June 1, 2026 (+119.51%) and its worst was May 8, 2026 (-39.29%). The stock moved 10% or more in a single session 31 times. It opened at least 5% above the previous day's high 6 times.
AIM ImmunoTech Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States.
Find more stocks like AIM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.